Category: 1056264-66-4

On July 1, 2021, Yu, Zhiyong; Li, Pan; Xu, Beidi; Zhou, Yu; Pang, Wei; Wen, Qiaodong; Shi, Yongqiang; Sun, Zhao; Lv, Meng published a patent.SDS of cas: 1056264-66-4 The title of the patent was PD-L1 antagonist compound and application. And the patent contained the following:

The invention disclosed a kind of PD-L1 antagonist, its preparation method and application. The claimed PD-L1 antagonist is shown in structure I (L1 = -CRARB-, -C(O)-; L2,L3 = -(CRCRD)p, -(CRCRD)p-NRa-(CRCRD)q-, -(CRCRD)p-O-(CRCRD)q-, carbonyl; W1,W2 = CRL or N; R1 = H, halo, nitro, etc.; R2-R5 = cyano, C3-6 cycloalkyl, C1-6 alkyl, etc.; Cy = (un)substituted Ph or six member heteroaryl, etc.; T,A = (un)substituted C1-6 alkyl, alkylenecycloalkyl, alkyleneheterocycloalkyl, etc.; m,o = 0, 1-2 integers). The claimed compound is prepared via multiple steps (procedure given). The prepared compound can be used as PD-L1 antagonist for preventing or treating immune-related disorders. The experimental process involved the reaction of 2-Bromo-3-chloro-6-fluorobenzaldehyde(cas: 1056264-66-4).SDS of cas: 1056264-66-4

The Article related to pd l1 antagonist preparation immune disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.SDS of cas: 1056264-66-4

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics

On September 12, 2008, Johnson, Christopher Norbert; Jones, David G.; Liang, Xi; Macpherson, David Timothy; Miller, Aaron B.; Naylor, Antoinette; Stanway, Steven James; Takle, Andrew Kenneth; Trani, Giancarlo published a patent.Related Products of 1056264-66-4 The title of the patent was Indazole derivatives as estrogen receptor beta mediators and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

The invention relates to indazole derivatives of formula I which have pharmacol. activities, to processes for their preparation, to compositions containing them and to uses of these compounds in the treatment of estrogen receptor beta (ER-β) mediated diseases. Compounds of formula I wherein Ra, Rb and Rc are independently halo, C1-4 alkoxy, C1-4 alkyl, C2-4 alkenyl, C1-5 alkanoyl, CF3, CF3O and CN; provided that when one of the substitutes is attached to the C-5 of the indazole bicycle, this substituent Ra is not methoxy; m is 0-3; n is 0-1; p is 0-4; m, n and p together is ≤ 5; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by debenzylation of 1-{3-fluoro-4-[(phenylmethyl)oxy]phenyl}-4-[(phenylmethyl)oxy]-1H-indazole. All the invention compounds were evaluated for their ER-β receptor binding ability. From the assay, it was determined that II and other tested compounds exhibited the pIC50 value of > 7. The experimental process involved the reaction of 2-Bromo-3-chloro-6-fluorobenzaldehyde(cas: 1056264-66-4).Related Products of 1056264-66-4

The Article related to indazole derivative preparation estrogen receptor mediator receptor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazoles and other aspects.Related Products of 1056264-66-4

Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics